Pharma Acronyms & Abbreviations Dictionary

Broader term than ADR; includes any harm caused by a drug including medication errors, overdoses, and ADRs.

Four pharmacokinetic parameters describing how a drug is processed by the body.

A response to a drug that is noxious, unintended, and occurs at doses normally used for prophylaxis, diagnosis, or therapy.

Any untoward medical occurrence in a clinical trial participant, not necessarily causally related to the study treatment.

FDA application for generic drug approval, demonstrating bioequivalence to a reference listed drug.

Biologically active component of a drug product that produces the intended therapeutic effect.

Enterprise pharmacovigilance case management software widely used in the pharmaceutical industry.

EU equivalent of DMF; confidential dossier on active substance filed by the manufacturer.

Document defining test methods and acceptance criteria used to verify equipment or system performance.

Integral of the drug concentration-time curve; measure of total systemic drug exposure.

Independent radiological assessment of tumor response performed by reviewers blinded to treatment allocation.

FDA application for biological product approval.

Document recording all activities, materials, and test results for a specific manufactured batch.

Official collection of standards for medicinal substances in the UK, published by the British Pharmacopoeia Commission.

Equivalent to BMR; complete record of the manufacture of a single batch.

Systematic quality process for identifying, investigating, and eliminating the root causes of actual or potential quality problems.

Controlled process for managing changes to validated processes, procedures, systems, or equipment to prevent unintended quality impacts.

European Pharmacopoeia certificate for excipients/APIs confirming compliance with Ph. Eur. monographs.

Former name of China's drug regulatory authority, now NMPA (National Medical Products Administration).

Regulatory framework emphasizing that manufacturing standards must be current; enforced by FDA under 21 CFR Parts 210/211.

EMA's scientific committee responsible for evaluating marketing authorization applications in the EU.

International organization that develops pharmacovigilance standards and reporting forms used globally.

Volume of plasma cleared of drug per unit time; key PK parameter for dosing interval calculations.

Peak drug concentration in plasma after dosing; key parameter for assessing drug exposure and safety.

Section of NDA/BLA covering the drug substance, drug product, and manufacturing process.

Document issued by the manufacturer certifying that test results for a specific batch meet predefined specifications.

Document certifying that a product or service conforms to specified requirements.

Former name of CHMP, the EMA scientific committee for human medicines.

Process parameter whose variability has a direct impact on a critical quality attribute; must be monitored and controlled.

Physical, chemical, biological, or microbiological property that must be within an appropriate limit to ensure product quality, safety, and efficacy.

Monitor employed by a sponsor or CRO who oversees clinical trial sites to ensure protocol compliance and data integrity.

Site-level staff member who manages the day-to-day operations of a clinical trial at an investigator site.

Paper or electronic form used for recording data for each trial subject as specified in the clinical protocol.

Company providing outsourced clinical research services to pharmaceutical, biotech, and medical device companies.

ICH E3-defined comprehensive report of a clinical trial integrating clinical and statistical descriptions, presentations, and analyses.

Documented process of validating computerized systems used in GMP environments per 21 CFR Part 11 requirements.

ICH-harmonized format for global drug submissions, organized into five modules.

Measure of variability expressed as the ratio of standard deviation to mean; same as RSD. Used to assess assay precision.

WHO statistical measure of drug utilization representing the assumed average maintenance dose per day for the drug's main indication.

Toxicity defining the maximum tolerated dose in a Phase 1 dose-escalation trial.

Independent committee reviewing unblinded safety and efficacy data during a trial; equivalent to DSMB.

Confidential information filed with FDA about facilities, processes, or articles used in manufacturing, processing, packaging, or storing a drug.

Finished dosage form (tablet, injection, etc.) containing the API plus excipients.

Documented verification that the proposed design of facilities, systems, and equipment is suitable for the intended purpose.

Same as API; the active ingredient before being formulated into the final drug product.

Independent committee of experts that reviews accumulating data during a clinical trial to monitor participant safety and study integrity.

Annual safety report submitted during clinical development under ICH E2F guidelines.

ICH guideline defining clinical safety data management including definitions and standards for expedited safety reporting.

ICH guideline for electronic transmission of individual case safety reports (ICSRs).

ICH guideline for periodic benefit-risk evaluation reports (PBRERs/PSURs).

ICH guideline for pharmacovigilance planning, including risk management.

Bayesian disproportionality measure used by FDA AERS for signal detection; estimates the true reporting ratio.

Drug concentration producing 50% of the maximum pharmacodynamic effect; key PD parameter.

Electronic form used in EDC systems to capture patient data in a clinical trial.

Standardized electronic format for regulatory submissions, required by FDA, EMA, and other agencies.

Software system used for collecting clinical trial data electronically, replacing paper CRFs.

Workplace safety, environmental compliance, and health protection programs in pharmaceutical manufacturing sites.

EU drug regulatory authority responsible for evaluating and supervising medicinal products in Europe.

Official EU drug quality standards; also abbreviated as Ph. Eur.

Integrated business management software (e.g., SAP) managing production, inventory, quality, and finance in pharma operations.

EMA's European spontaneous adverse event reporting database for collecting and analyzing ICSRs from EEA member states.

Web portal for submitting individual case safety reports (ICSRs) to the EMA EudraVigilance database.

Fraction of an administered dose that reaches systemic circulation; 100% for IV administration.

US spontaneous reporting database containing ICSRs submitted to FDA; publicly accessible.

US drug regulatory authority responsible for protecting public health by ensuring the safety and efficacy of drugs, biologics, and medical devices.

The final drug product in its packaged and labeled form ready for patient use; synonymous with Drug Product.

First administration of a new investigational drug to human subjects in a Phase 1 clinical trial.

Equivalent to FIH; first human administration of a new drug candidate.

ISPE industry guidance framework for the lifecycle-based validation of automated systems and software used in GMP environments.

Analytical separation technique for volatile and semi-volatile compounds; used for residual solvents and impurity testing.

ICH E6 international quality standard for the design, conduct, performance, monitoring, auditing, recording, and reporting of clinical trials.

Guidelines ensuring pharmaceutical products are consistently stored, transported, and handled to maintain quality throughout the distribution chain.

Basic cleanliness, organization, and maintenance practices in manufacturing and laboratory areas.

Regulatory standards governing the manufacturing, testing, and quality assurance of pharmaceutical products.

Guidelines for maintaining proper conditions during pharmaceutical storage to preserve product quality.

Generic term for a national drug regulatory agency.

Canadian federal department responsible for drug regulation and health policy.

Animal dose converted to equivalent human dose using body surface area scaling factors for FIH dose selection.

Filter standard for cleanrooms and biosafety cabinets, capturing ≥99.97% of particles ≥0.3 microns.

Primary analytical technique in pharmaceutical QC for assay, purity, and impurity testing.

Critical utility system for maintaining temperature, humidity, and air cleanliness in pharmaceutical cleanrooms.

Document summarizing clinical and nonclinical data on an investigational product relevant to its study in human subjects.

Bayesian disproportionality measure developed by the Uppsala Monitoring Centre for signal detection in VigiBase.

Drug concentration inhibiting 50% of the target (enzyme, receptor, or cell) activity; key parameter in drug discovery.

Document and process by which a subject voluntarily confirms willingness to participate in a clinical trial after being informed of all relevant aspects.

ICH guideline for analytical method validation covering accuracy, precision, linearity, range, specificity, LOD, and LOQ.

Highly sensitive elemental analysis technique used for elemental impurity testing per ICH Q3D.

Standardized report of a single suspected adverse reaction to a medicine, submitted to regulators and entered into safety databases.

Plural form; collection of individual reports of suspected adverse reactions used for pharmacovigilance signal detection.

Same as DSMB/DMC; independent committee reviewing trial safety data to protect participant welfare.

EU/international equivalent of IRB; an independent body that reviews and approves clinical trial protocols for ethical acceptability.

FDA application that must be filed before a new drug or biologic can be tested in humans in the US.

Official standards for drugs manufactured and sold in India, published by the Indian Pharmacopoeia Commission.

Testing and monitoring performed during manufacturing to ensure the process is under control and the product meets specifications.

Documented verification that equipment or systems have been installed correctly according to specifications.

Spectroscopic technique for identifying functional groups and confirming drug identity by matching IR spectra.

US ethics committee responsible for reviewing and approving clinical research to protect the rights and welfare of research subjects.

Modified RECIST criteria designed for immunotherapy trials to account for atypical response patterns such as pseudoprogression.

NDA section compiling and analyzing efficacy data across all studies in a drug development program.

NDA section compiling safety data across all studies in a drug development program.

Analysis strategy that includes all randomized patients in the group to which they were assigned, regardless of protocol compliance.

Official standards for pharmaceuticals in Japan, published by the Ministry of Health, Labour and Welfare.

Titration method specifically designed for water determination in pharmaceutical materials; highly sensitive and specific.

Directional, non-turbulent airflow used in cleanrooms and biosafety cabinets to prevent contamination.

Combined analytical platform coupling HPLC separation with MS detection; used for trace impurity identification.

Dose lethal to 50% of a test population in preclinical toxicology studies.

Software platform for managing laboratory samples, data, workflows, and reporting in a GMP environment.

Missing data imputation method where the last observed value is used for all subsequent missing time points.

Lowest amount of analyte detectable with statistical confidence; signal-to-noise ratio of approximately 3:1.

Lowest amount of analyte that can be quantified with acceptable precision and accuracy; S/N approximately 10:1.

EU regulatory approval status granting permission to market a medicinal product.

EU equivalent of an NDA; application submitted to EMA or national agencies for marketing approval.

Approved template from which individual batch manufacturing records are derived for each production run.

Equivalent to PDUFA for medical devices; sets FDA review timelines and fee structures for device applications.

Lowest dose that produces a desired therapeutic effect in a dose-response relationship.

Standardized international medical terminology used for regulatory communication, including adverse event coding in ICSRs.

UK's independent regulator for medicines and medical devices since Brexit.

ITT analysis with pre-specified exclusions defined in the statistical analysis plan before unblinding.

Statistical method commonly used in clinical trials with continuous repeated-measures outcomes; handles missing data without imputation.

Specific biochemical or physiological interaction through which a drug produces its pharmacological effect.

Production planning and inventory control system used in pharmaceutical manufacturing.

Analytical technique measuring mass-to-charge ratios of ions; used for molecular identification and impurity profiling.

Highest dose that does not cause unacceptable toxicity; the primary endpoint of most Phase 1 oncology trials.

Novel biological drug not previously approved; includes monoclonal antibodies, proteins, and gene therapies.

Novel small molecule drug compound not previously approved by any regulatory authority.

FDA application for approval of a new brand-name drug, including full safety, efficacy, and CMC data.

Same as NCE; FDA designation for new drug active ingredients not previously approved.

China's drug regulatory authority (formerly CFDA), responsible for approving and supervising drugs, medical devices, and cosmetics.

Spectroscopic technique for structure elucidation and purity assessment; provides detailed molecular structure information.

Highest tested dose at which no adverse effects are observed in toxicology studies; basis for human dose selection.

Highest dose at which no effects (adverse or otherwise) are observed in toxicology studies.

Post-trial period where participants who completed a blinded study may receive active treatment and continue to be followed.

Documented verification that equipment and systems operate within defined ranges under normal operating conditions.

Test result that falls outside the predefined acceptance criteria established in specifications or regulatory filings.

Test result that is within specification but inconsistent with historical trends, requiring investigation.

Documented verification that equipment operates correctly within defined parameters throughout all anticipated operating ranges.

FDA/ICH framework for designing, analyzing, and controlling pharmaceutical manufacturing processes through timely measurements of critical quality attributes.

ICH E2C(R2) global pharmacovigilance report submitted at defined intervals to assess the benefit-risk balance of marketed products.

Study of the biochemical and physiological effects of drugs and their mechanisms of action at target sites.

US law setting FDA review timelines and fee structures for new drug and biologic applications.

Abbreviated form of the European Pharmacopoeia; same as EP.

Physician or scientist responsible for the conduct of a clinical trial at a specific investigation site.

International cooperation scheme for harmonizing GMP standards and mutual recognition of inspections.

EU patient-facing drug information document included in every medicine pack.

Study of how the body absorbs, distributes, metabolizes, and excretes a drug (ADME).

Japan's drug regulatory authority responsible for review, relief, and safety of pharmaceuticals and medical devices.

Early clinical evidence demonstrating that a drug has the intended biological activity or clinical effect.

Analysis limited to the subset of patients who completed the trial without major protocol deviations.

Documented verification that equipment and ancillary systems perform consistently to produce a product meeting specifications under actual production conditions.

Frequentist disproportionality measure comparing the proportion of reports for a drug-event pair relative to all events for that drug.

EU pharmacovigilance report submitted at defined intervals after marketing authorization to evaluate ongoing benefit-risk.

Specific MedDRA term used for coding adverse events; a distinct medical concept within a MedDRA System Organ Class.

The science and activities relating to the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problem.

Systematic approach to pharmaceutical development, beginning with predefined objectives and emphasizing product and process understanding and control.

Computational modeling approach relating chemical structure to biological activity for drug discovery.

Standardized criteria for measuring tumor response to treatment in solid tumor oncology trials.

FDA-required safety program for high-risk drugs to ensure benefits outweigh risks; may include medication guides, communication plans, or restricted distribution.

Document describing known and potential risks of a medicine and how those risks are prevented or minimized.

Case/non-case disproportionality method for signal detection; compares the odds of a specific adverse event for a given drug vs. all others.

Dose of an investigational drug selected from Phase 1 dose-escalation for use in subsequent efficacy trials.

Standard deviation expressed as a percentage of the mean; same as CV. Used to assess analytical precision.

Adverse event that results in death, is life-threatening, requires hospitalization, results in disability, or is a congenital anomaly.

EU equivalent of prescribing information; official document describing properties and approved conditions of use for a medicine.

Grouping of MedDRA terms covering a medical concept used for broad safety searches across multiple preferred terms.

Documented procedure describing how to perform a specific activity to ensure consistency and regulatory compliance.

Certified reference material with traceable values; used for method validation and instrument calibration.

SAE that is both unexpected (not in the IB) and judged to be possibly related to study treatment; requires expedited regulatory reporting.

Time required for the plasma drug concentration to decrease by 50%; determines dosing interval.

Australia's regulatory authority for therapeutic goods including medicines, medical devices, and biologicals.

Ratio of the toxic dose to the therapeutic dose (LD50/ED50); measure of drug safety margin.

Time after dosing at which the peak drug plasma concentration (Cmax) is reached.

Strategic document defining the desired characteristics of a drug product to guide development decisions.

Drug concentration range between the minimum effective concentration and the minimum toxic concentration.

Document defining what a system, equipment, or facility must do to meet user and regulatory requirements.

Official US drug quality standards compendium published by the US Pharmacopeial Convention.

Spectrophotometric technique measuring absorbance in UV and visible light ranges; used for drug identification and purity.

Apparent volume in which a drug distributes throughout the body; affects drug concentration at steady state.

WHO's global database of individual case safety reports, managed by the Uppsala Monitoring Centre; the world's largest pharmacovigilance database.

WHO collaborating centre for international drug monitoring; manages VigiBase and develops pharmacovigilance methods.